Advertisement
U.S. markets closed
Advertisement

Armata Pharmaceuticals, Inc. (ARMP)

NYSE American - NYSE American Delayed Price. Currency in USD
Visitors trend2W10W9M
2.3700+0.1800 (+8.22%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close2.1900
Open2.2300
Bid1.9700 x 800
Ask2.4700 x 800
Day's Range2.1400 - 2.3900
52 Week Range0.8300 - 5.2600
Volume11,033
Avg. Volume19,485
Market Cap85.667M
Beta (5Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-1.6500
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ARMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Armata Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Rating
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • PR Newswire

    Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2023, and provided a corporate update.

  • PR Newswire

    Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that topline data from the Company's Phase 1b/2a SWARM-P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be m

  • PR Newswire

    Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

    Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its Chief Medical Officer, Mina Pastagia, M.D., MS, will deliver a presentation at Phage Futures: Global Digital Summit 2023, which is being held virtually on October 25th.